Search

Displaying results 861 - 870 of 5878 in total
  1. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub … [A261831] Etrasimod was approved on October 13, 2023, by the FDA under the brand name VELSIPITY for the treatment of adults with moderately to severely active ulcerative colitis.

  2. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … Patients with moderate-to-severe atopic dermatitis report reduced quality of life and often face limited treatment options.

  3. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    due to non-selective steroidal activities [A275513, A275514]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].

  4. Drug

    Bemotrizinol

    go.drugbank.com/drugs/DB11206
    Approved

    Compared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212]. … It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application [A19212, A32909].

    Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23
  5. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A2301, L38978] Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration.

  6. Drug

    Tilactase

    go.drugbank.com/drugs/DB13761
    ApprovedInvestigational

    [A32591] It is considered by the WHO as part of the International Nonpropietary Names for Pharmaceutical Substances.[L2338] … It is produced as a chewable tablet that has to be taken before the consumption of a lactose-containing meal.

  7. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. … Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative comprising a 50:50 mixture of two isomers: [CL-315555] and [CL-315585].

  8. Drug

    Lebrikizumab

    go.drugbank.com/drugs/DB11914
    ApprovedInvestigational

    Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12

  9. Drug

    Valaciclovir

    go.drugbank.com/drugs/DB00577
    ApprovedInvestigational

    One major use of valacyclovir is the treatment of genital herpes episodes or outbreaks. … Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades.

    Products: Co Valacyclovir, VALACICLOVIR MYLAN GENERICS
  10. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    to this therapeutic target. … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.